Why the study?
Is immunohistochemistry for MDM2, CDK4, and p16 expression useful for diagnosing liposarcoma subtypes in the head and neck region?
Is immunohistochemistry for MDM2, CDK4, and p16 expression useful for diagnosing liposarcoma subtypes in the head and neck region?
Immunohistochemistry detecting MDM2, CDK4, and p16 expression is a useful diagnostic tool for identifying subtypes of rare head and neck liposarcomas.
Answers are grounded in this paper and cite their sources.
Case report of rare head-neck liposarcoma; leaves open optimal subtype-specific management and molecular integration.
Liposarcoma is a commonly encountered sarcoma, that arises predominantly in the extremities or retroperitoneum. According to a study conducted by the Armed Forces Institute of Pathology (AFIP), liposarcoma accounts for approximately 14% of all sarcomas, and only 3.8% of all liposarcomas are found in the head and neck region. Liposarcoma has been classified into four histological subtypes. The clinical features depend on the type of the tumor. Recently, numerous advances have been made in molecular and biologic analyses of liposarcomas, and several gene mutations have been found. These findings are useful for diagnosis of the tumor subtypes. We report two cases of liposarcoma arising in the head and neck region, in which immunohistochemistry was useful for the diagnosis.
No takes yet. Share an insight, caveat, or question.
Kano et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: